secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001193125-21-323057
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M
--------------------------------------------------------------------

- Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).
- Net income $1.6M, down from $6.5M YoY; non-GAAP net income $4.1M vs $6.7M.
- Operating expenses $18.3M, up 106% YoY due to public company costs and R&D investment.
- Cash $377M; installed base expanded to 970 instruments with 115 placements in Q3.
- Announced acquisition of Tonbo Biosciences' cell analysis business to enhance reagent portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/0001193125-21-323057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/d257430d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-323057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer